Icrucumab, an innovative monoclonal antibody, is presently undergoing thorough clinical testing for its treatment in various inflammatory diseases. Early research suggest a promising mechanism of action, selectively targeting the impact of IL-17, a key cytokine involved in autoimmune processes. T

Sibeprenlimab, formerly known as VIS649, represents a novel monoclonal antibody demonstrating impressive capability in the treatment of immune-mediated disorders. This distinct approach inhibits C5a, a key mediator participating in the autoimmune pathway, presenting a distinct advantage over exis